Condition: Post-bariatric Surgery · Sponsor: The University of Texas Health Science Center at San Antonio
The overall goal of this project is to understand the mechanisms by which gastric bypass surgery improves glucose metabolism. The central hypothesis guiding this project is that the reconfiguration of intestinal transit with the Roux-en-Y will increase the release of insulinotropic GI hormones, termed incretins that improve insulin secretion and glucose metabolism. The study is divided into three specific aims. 1. To determine the role of incretin hormones on insulin secretion in patients with gastric bypass surgery using intravenous-oral hyperglycemic clamp. 2. To compare incretin effect and glucose tolerance among patient who suffer from hypoglycemia after RYGB and asymptomatic surgical and non-surgical individuals. 3. To quantify the contribution of GLP-1 to incretin effect enhancement following surgery.
This description comes directly from the study's public registry record.
Marzieh Salehi, MD MS · 210-567-6691 · salehi@uthscsa.edu
Jennifer Foster, MSN · 210-450-8696 · fosterj6@uthscsa.edu
Always discuss trial participation with your own doctor first.
| Texas Diabetes Institute - University Health System | San Antonio, Texas, United States | Recruiting |
| South Texas Veterans Health Care System | San Antonio, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT01803451